New insight into brain disease therapy: nanomedicines-crossing blood–brain barrier and extracellular space for drug delivery. (2nd December 2022)

• Record Type: Journal Article
• Authors: Gu, Ziqi; Chen, Haishu; Zhao, Han; Yang, Wanting; Song, Yilan; Li, Xiang; Wang, Yang; Du, Dan; Liao, Haikang; Pan, Wenhao; Li, Xi; Gao, Yajuan; Han, Hongbin; Tong, Zhiqian
• Is Part Of: Expert opinion on drug delivery. Volume 19:Number 12(2022)
• Page Start: 1618
• Page End: 1635
• Publication Date: 2022-12-02
• Subjects: Blood-brain barrier (BBB) -- brain diseases -- drug delivery -- extracellular space (ECS) -- interstitial fluid (ISF) -- nanomedicines; Drug delivery devices -- Periodicals; Drug delivery systems -- Periodicals; 615.605
• DOI: 10.1080/17425247.2022.2139369
• Languages: English
• ISSNs: 1742-5247

Abstract

ABSTRACT: Introduction: Brain diseases including brain tumor, Alzheimer's disease, Parkinson's disease, etc. are difficult to treat. The blood–brain barrier (BBB) is a major obstacle for drug delivery into the brain. Although nano-package and receptor-mediated delivery of nanomedicine markedly increases BBB penetration, it yet did not extensively improve clinical cure rate. Recently, brain extracellular space (ECS) and interstitial fluid (ISF) drainage in ECS have been found to determine whether a drug dissolved in ISF can reach its target cells. Notably, an increase in tortuosity of ECS associated with slower ISF drainage induced by the accumulated harmful substances, such as: amyloid-beta (Aβ), α-synuclein, and metabolic wastes, causes drug delivery failure. Areas covered: The methods of nano-package and receptor-mediated drug delivery and the penetration efficacy of nanomedicines across BBB and ECS are assessed. Expert opinion: Invasive delivering drug via ECS and noninvasive near-infrared photo-sensitive nanomedicines may provide a promising benefit to patients with brain disease.